---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-013992"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2022-03-22T23:59:59+00:00"
generated_at: "2026-06-26T21:04:53.575482+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma extends share repurchase program to July 31, 2022; $3.6M remaining authorization.

## Summary
- Board extended existing share repurchase program through July 31, 2022, with $7M total authorization.
- Since Nov 2021, 475,157 shares repurchased for ~$3.4M; $3.6M remaining as of March 21, 2022.
- Company had $70.7M cash, equivalents, and marketable securities as of Dec 31, 2021.
- Repurchases may occur on open market or privately; program may be suspended at any time.

## SEC filing metadata
- accession: 0001213900-22-013992
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2022-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000121390022013992/0001213900-22-013992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000121390022013992/ea157208-8k_lantern.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-013992
- JSON: https://secwatch.observer/filing/0001213900-22-013992.json
- Plain text: https://secwatch.observer/filing/0001213900-22-013992.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.